POSTER SESSION II Monday, March 8, 2004   —  1:00 - 4:30 PM Exhibit Hall B and C GYNECOLOGIC PATHOLOGY 106 High Frequency of b-Catenin Nuclear Expression and Mutations in Ovarian Endometrioid Tumors of Borderline Malignancy (877) E Oliva, EF Brachtel, RA Soslow, C Sanchez, G Moreno, J Palacios - Massachusetts General Hospital, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Centro Nacional de Investigaciones Oncologicas, Madrid, Spain 107 Telomerase Reverse Transcriptase (TERT) and Proliferation Activity in Ovarian Serous Borderline Tumers, Micropapillary Serous Tumors and Invasive Serous Carcinoma: A Comparative Immunohistochemical Study of 42 Cases (852) F Liu, CJ Sung, C Zhang, MR Quddus, HY Huang, MM Steinhoff, WD Lawrence - Women & Infants Hospital, Brown Medical School, Providence, RI; Chang Gung Memorial Hospital, Kaoshiung, Taiwan 108 Autoimplants Involving Serous Borderline Tumors of the Ovary: A Clinicopathologic Study of 30 Cases (894) SE Rollins, RH Young, DA Bell - Massachusetts General Hospital, Boston, MA 109 CRxA-01 and L523 Expression in Serous Neoplasms of the Ovary: Potential Role in Differentiating Serous Tumors of Low Malignant Potential from Serous Carcinomas (813) A Ciampa, B Chaitanya, A Khan, K Rock, H Ball, B Xu - University of Massachusetts Medical School, Worcester, MA; Corixa Corporation, Seattle, WA 110 Microsatellite Instability and Alteration of Expression of hMLH1 and hMSH2 in Ovarian Clear Cell Carcinoma (804) Q Cai, C Albarracin, DG Rosen, R Zhong, W Zheng, R Broaddus, R Luthra, J Liu - MD Anderson Cancer Center, Houston, TX; Yale Universtiy, New Heaven, CT 111 Can the Pattern of WT-1 Expression Reliably Distinguish between Synchronicity and Metastasis in Endometrioid and Serous Carcinomas of the Müllerian System? (903) CJ Sung, MR Quddus, M Eklund, MM Steinhoff, WD Lawrence - Women & Infants Hospital and Brown Medical School, Providence, RI 112 WT-1 Expression in Ovarian Epithelial Tumors and Endometrial Serous Carcinoma (837) T Kiyokawa, Y Kanetsuna, T Harada, M Sasaki, M Suzuki, M Kawakami - Jikei University School of Medicine, Minato-ku, Tokyo, Japan 113 RAF / RAS Mutations in Ovarian Neoplasms (908) BK Warren, NLG Sieben, P Macropoulos, GMJM Roemen, SM Kolkman-Uljee, M Tretiakova, T Krausz, AM Flanagan - University of Maastricht, Netherlands; University College London, United Kingdom; Leiden University Medical Center, Netherlands; The University of Chicago 114 E2F-1 Expression Correlates Significantly with Apoptotic Index and Ki-67 Expression in Ovarian Tumors (897) J Seo, G Ahn - Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 115 Low Expression of C-kit Associated with High Expression of Ki-67 and Poor Prognosis in Advance Ovarian Serous Carcinoma (SOC) (836) I Khalifeh, S Bandyopadhyay, JM Malone, AR Munkarah, WD Lawrence, R Ali-Fehmi - Karmanos Cancer Institute, Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI; Brown University School of Medicine, Providence, RI 116 Loss of p16 Expression Is of Prognostic Significance in High-Grade Advanced-Stage Ovarian Cancer (882) RL Parker, E Yorida, M Cheang, DG Huntsman, D Miller, P Hoskins, D Demetrick, CB Gilks - University of Calgary, Calgary, AB; Genetic Pathology Evaluation Centre, Vancouver General Hospital, University of BC andBritish Columbia Cancer Agency, Vancouver, BC, Canada 117 Cyclin E Expression in Ovarian Cancer: Correlation with Clinico-Pathological and Molecular Features (826) D Hardisson R Cassia, G Hernández-Cortés, JI Sánchez-Méndez, A Suárez, A Domínguez-Cáceres, J Palacios - Hospital Universitario La Paz, Madrid, Spain; School of Medicine, Autonomous University of Madrid (UAM), Madrid, Spain; Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain 118 Cyclin E Is an Independent Prognostic Marker for Epithelial Ovarian Carcinoma (895) DG Rosen, G Yang, A Malpica, MT Deavers, J Liu - MD Anderson Cancer Center, Houston, TX 119 ret-PTC-1: A Novel Chimeric Transcript Occurring in Ovarian Serous Surface Carcinomas: Preliminary Results (823) RJ Flavin, SP Finn, P Symth, EM O'Regan, E Gaffney, JJ O'Leary, OM Sheils - Trinity College Medical School, Dublin, Ireland 120 Expression of TTF-1 in Primary Ovarian Surface Epithelial Carcinomas: A Study of 53 Cases (887) MR Quddus, BI Aswad, CJ Sung, RA DeLellis, WD Lawrence - Women & Infants Hospital and Brown Medical School, Providence, RI; Rhode Island Hospital, Providence, RI 121 Correlation of Cancer-Testis Antigen Expression with P-glycoprotein, p53, p63, and bcl-2 in Ovarian Serous Carcinomas (917) E Yakirevich, E Sabo, Y Sova, O Lavie, GC Spagnoli, MB Resnick - Carmel Medical Center, Haifa, Israel; University Hospital, Basel, Switzerland 122 QM Gene Expression in Normal Ovary and in Serous Ovarian Carcinoma (791) R Ali-Fehmi, H Nassar, V Pansare, S Bandyopadhyay, F Sarkar, AR Munkarah, J Liao - Wayne State University School of Medicine, Detroit, MI; Karmanos Institute of Cancer Research, Detroit, MI 123 Overexpression of IGFBP2 and IGFBP5 Correlates with High Histologic Grades and Advanced Stages in Ovarian Cancers (907) H Wang, D Rosen, H Wang, GN Fuller, W Zhang, J Liu - The University of Texas M.D. Anderson Cancer Center, Houston, TX 124 The Impact of Destructive Stromal Invasion on Outcome in Stage I, Low Grade Endometrioid and Mucinous Ovarian Carcinomas (808) S Chen, MM Leitao, C Tornos, RA Soslow - Memorial Sloan-Kettering Cancer Center, New York, NY 125 Aggressive Behavior of Stage I Ovarian Mucinous Tumors without Destructive Stromal Invasion (860) CL Ludwick, CB Gilks, H Yaziji, PB Clement - Vancouver General Hospital and University of BC, Vancouver, Canada; PhenoPath Laboratories, Seattle, WA 126 Foci/Nodules of Anaplastic Carcinoma in Mucinous Cystic Ovarian Tumors: A Clinicopathologic Study of 34 Cases (885) C Provenza, J Prat, RH Young - Hospital de la Santa Creu i Sant Pau. Autonomous University of Barcelona, Barcelona, Spain; Massachusetts General Hospital, Boston, MA 127 Frequent Chromosome 18q Loss in Ovarian Mucinous, and Appendiceal Mucinous and Non-Mucinous Adenocarcinomas (820) MT Deavers, A Malpica, EG Silva, A Rashid - M. D. Anderson Cancer Center, Houston, TX 128 CDX-2 Immunoreactivity Can Serve as a Useful Marker in Differential Diagnosis between Primary and Metastatic Ovarian Carcinomas (906) L Tornillo, H Moch, P-A Diener, G Singer - University of Basel, Basel, Switzerland; Cantonal Hospital St. Gallen, St. Gallen, Switzerland 129 Immunohistochemical Expression of Mesothelin and Fascin in Primary Ovarian Mucinous Neoplasms and Metastatic Pancreatic Mucinous Carcinomas in the Ovaries (806) D Cao, H Ji, BM Ronnett - The Johns Hopkins Hospital, Baltimore, MD 130 Use of Novel Immunohistochemical Markers Expressed in Colonic Adenocarcinoma To Distinguish Primary Ovarian Tumors from Metastatic Colorectal Carcinoma (857) S Logani, E Oliva, PM Arnell, MB Amin, RH Young - Emory University School of Medicine, Atlanta, GA; Massachusetts General Hospital, Harvard Medical School, Boston, MA 131 Immunohistochemical Differentiation between Ovarian and Breast Adenocarcinomas (888) G Rasty, A Covens, M Khalifa - Sunnybrook & Women's College Health Sciences Centre, Toronto, ON, Canada; Southwest Medical Center, Oklahoma, OK 132 Metastatic Endocervical Adenocarcinomas Simulating Primary Ovarian Surface Epithelial Neoplasms (822) E Elishaev, M Srodon, RJ Kurman, BM Ronnett - The Johns Hopkins Medical Institutions, Baltimore, MD